Based on this transaction and a few others from Corporate Insiders of ALIM that Bought 57,257,868 worth of shares in the last 3 months, the Insider Confidence level of Alimera is trending Up.
Since these insiders have unique insights into what's happening at Alimera, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for ALIM:
- Partners Caligan - director, 10 percent owner:, Bought $1,962,810 worth of shares on 4 days ago
- Adam Morgan - 10 percent owner, Bought $2,383,232 worth of shares on 4 months ago
- Alto Palo - 10 percent owner, Sold $314,117 worth of shares on 5 months ago
- STANLEY MORGAN - 10 percent owner, Sold $1,137,500 worth of shares on 1 year ago
In addition, TradingView issued a sell rating for ALIM over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on Alimera, ALIM but please do your own research.
ALIM Summary: Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
- Recent Last Price: $3.19
- Price Change: -$0.13, -3.92%
- Yearly Gain: -38.29%
- Market Cap: $29.22M
- P/E Ratio: -1
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to ALIM, you should consider joining TipRanks.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.